A marker for Stevens-Johnson syndrome ...: ethnicity matters (Q34485108)

2 August 2017

A marker for Stevens-Johnson syndrome ...: ethnicity matters (English)

1 reference

2 August 2017

Stevens–Johnson syndrome

1 reference

C Lonjou

1

0 references

Alain Hovnanian

object named as

A Hovnanian

9

0 references

author name string

L Thomas

2

1 reference

2 August 2017

N Borot

3

1 reference

2 August 2017

N Ledger

4

1 reference

2 August 2017

C de Toma

5

1 reference

2 August 2017

H LeLouet

6

1 reference

2 August 2017

E Graf

7

1 reference

2 August 2017

M Schumacher

8

1 reference

2 August 2017

M Mockenhaupt

10

1 reference

2 August 2017

J-C Roujeau

11

1 reference

2 August 2017

RegiSCAR Group

12

1 reference

2 August 2017

17 January 2006

1 reference

The Pharmacogenomics Journal

2 August 2017

1 reference

2 August 2017

6

1 reference

2 August 2017

265-268

1 reference

2 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.tpj.6500356

2 August 2017

0 references

cites work

Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500356

Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500356

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500356

Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500356

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500356

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500356

Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500356

Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500356

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500356

MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500356

The three-dimensional structure of peptide-MHC complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500356

Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500356

Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500356

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500356

Genetic susceptibility to toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500356

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.TPJ.6500356

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference